Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282906 · ClinicalTrials.gov registry record · NA
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 257
- Enrollment target
NCT00282906 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 257 participants.
The verdict
NCT00282906, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 257 participants
- Enrollment target
Study Summary
This is an National Institute of Health (NIH) funded, investigator-initiated, single center prospective study to investigate the ability of the new dual-modality positron emission tomography and computed tomography (PET-CT) imaging systems in comparison to conventional imaging methods in assessing treatment response in men with metastatic prostate cancer. The investigators will enroll two groups of men with stage IV metastatic prostate cancer, each group will be comprised of 160 patients. * Group I: men with newly diagnosed hormone-responsive measurable metastatic disease who will be treated with androgen-ablation therapy * Group II: men with newly-developed hormone-refractory measurable metastatic disease who will be treated with chemotherapy and /or other therapies for hormone refractory disease To be eligible, men in either group must have rising serum prostate specific antigen (PSA) level - defined as at least 2 consecutive rises in PSA documented over a reference value (1st measure within 28 days prior to recruitment). The first rising PSA (2nd measure) should be taken at least 14 days after the reference value. A confirmatory PSA measure (3rd measure) obtained at least 14 days after the 2nd measure is required and must be greater than the 2nd measure. Additionally, patients must have a serum PSA concentration of at least 2 ng/mL in addition to increasing PSA to be eligible. Patients will be followed with the PET-CT at 4, 8, and 12 months after the initiation of androgen ablation therapy (Group I) or chemotherapy (Group II).
Interventions
- DEVICE hybrid PET-CT imaging system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2005-10-03 |
| Est. Completion | 2014-08-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282906
The ClinicalTrials.gov registry entry for NCT00282906 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hybrid PET-CT imaging system is the first listed.
NCT00282906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282906 about?
NCT00282906 is a clinical study titled "FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer". This is an National Institute of Health (NIH) funded, investigator-initiated, single center prospective study to investigate the ability of the new dual-modality positron emission tomography and computed tomography (PET-CT) imaging systems in comparison to conventional imaging methods in assessing t...
What is the current status of trial NCT00282906?
This trial is currently completed. It is a NA study. The enrollment target is 257 participants. The study started on 2005-10-03. Estimated completion is 2014-08-19.
What interventions are being tested in trial NCT00282906?
The interventions under investigation include: hybrid PET-CT imaging system (DEVICE).
Who is sponsoring clinical trial NCT00282906?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.